

# Protracted exercise tolerance post-coronavirus disease 2019 in endurance athletes: A survey



## Authors:

Cheryl A. Haley<sup>1</sup>   
Heleen van Aswegen<sup>1</sup>   
Elena Libhaber<sup>2</sup>   
Benita Olivier<sup>1</sup>

## Affiliations:

<sup>1</sup>Department of  
Physiotherapy, Faculty of  
Health Sciences, University of  
the Witwatersrand,  
Johannesburg, South Africa

<sup>2</sup>Research Office, Faculty of  
Health Sciences, University of  
the Witwatersrand,  
Johannesburg, South Africa

## Corresponding author:

Cheryl Haley,  
cheryl@ourphysio.co.za

## Dates:

Received: 27 Mar. 2024  
Accepted: 03 June 2024  
Published: 14 Aug. 2024

## How to cite this article:

Haley, C.A., Van Aswegen, H.,  
Libhaber, E. & Olivier, B., 2024,  
'Protracted exercise tolerance  
post-coronavirus disease 2019  
in endurance athletes: A  
survey', *South African Journal  
of Physiotherapy* 80(1), a2063.  
<https://doi.org/10.4102/sajp.v80i1.2063>

## Copyright:

© 2024. The Authors.  
Licensee: AOSIS. This work  
is licensed under the  
Creative Commons  
Attribution License.

**Background:** The global coronavirus disease 2019 (COVID-19) pandemic irrevocably influenced our lives, yet research in a diversity of countries is lacking. Cardiorespiratory fitness may be impaired for up to a year post-COVID-19 infection.

**Objectives:** Our study aimed to compare acute and exertional symptoms, fatigue, and exercise performance in masters-age endurance athletes according to their return-to-sport status.

**Method:** A cross-sectional survey-based observational study of long-distance runners and cyclists was conducted. Data were stratified into two groups: those who returned to their pre-illness level of sport and those who did not and were compared statistically.

**Results:** A total of 308 survey responses were included in the analysis. The mean age of the athletes was 44.9 + 10.2 years, with 55.2% being male. The group that did not return to their pre-illness level of sport (31.5%) had more post-COVID sequelae, worse illness severity, with a higher frequency of resting and exertional symptoms, notably fatigue and dyspnoea. Decreased exercise capacity was correlated with increased physical fatigue scores.

**Conclusion:** Almost one-third of endurance athletes suffered protracted exercise tolerance post-COVID-19. Long-term symptoms may be more consequential in this athlete population.

**Clinical Implications:** Symptoms that may indicate cardiopulmonary consequences in recreational athletes should be investigated in order to facilitate return to sport and the important mental and physical benefits thereof. This will augment outcomes after respiratory tract infections and management of return to sport and expectations of endurance athletes.

**Keywords:** COVID-19; endurance athletes; return to sport; exercise capacity; fatigue.

## Introduction

The global coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has irrevocably influenced our lives. Extensive research has explored this disease and its devastating consequences on the world's population and concurrently enhanced global knowledge of respiratory illnesses (Burgstahler et al. 2023). Comorbid diseases and a lack of regular physical activity predispose individuals to a more severe expression of COVID-19 (Chen et al. 2020; Snyders et al. 2022). However, high-intensity exercise may lower immune function and increase susceptibility to upper respiratory tract infections (Agha-Alinejad et al. 2022). Cardiorespiratory fitness is now classed as a vital sign (Mihalick et al. 2021), thus lagging athlete health and the hindrance of persistent symptoms in resuming pre-illness level of sport is worth assessing (Schroeder et al. 2023).

Coronavirus disease 2019 is a multifaceted disease with manifestations like no other virus, such as blood clotting and long-standing fatigue and dyspnoea (Schwellnus et al. 2021). The cardiovascular consequences of COVID-19 are by far the most threatening and range from peri-myocarditis, arrhythmias, thromboembolism, myocardial infarction, to sudden death (Monosilio et al. 2023). However, according to the American College of Cardiology (ACC) 2022 expert consensus statement, there is fortunately a low prevalence (Gluckman et al. 2022). Long-term respiratory sequelae are more likely post-COVID-19 (Durstensfeld et al. 2022). Pulmonary limitations have been found to be responsible for low exercise tolerance up to 1-year post-COVID-19 infection (Braga et al. 2023), even after mild illness (Vollrath et al. 2022).

Acute COVID-19 symptoms are categorised as asymptomatic, mild, moderate, severe, and critical illness according to the National Institute of Health (COVID-19 Treatment Guidelines 2023). Mild illness symptoms include malaise and/or fatigue, headache, myalgia, ageusia and/or anosmia,

## Read online:



Scan this QR  
code with your  
smart phone or  
mobile device  
to read online.



cough, fever, and diarrhoea and/or vomiting. Symptoms associated with moderate illness include dyspnoea and clinical evidence of lower respiratory disease on imaging with normal oxygen saturation ( $\geq 94\%$  on room air). Individuals with severe illness present with respiratory distress and dyspnoea with oxygen saturation of  $< 94\%$ , and critical illness includes respiratory failure, septic shock and multiorgan failure. In our study, the term long-COVID is used for new or persistent symptoms after 4 weeks post onset of illness as defined by the National Institute for Health and Care Excellence (NICE 2021). Fatigue is a multidimensional and subjective symptom that may or may not relate to other physiological factors (Smets et al. 1995).

During the early phase of the pandemic, most studies explored symptom severity and duration in collegiate elite athletes. There remains a paucity of literature concerning the masters athlete (over the age of 35 years) (Juhász et al. 2022). Endurance athletes require the ability to resist fatigue; typically training high volumes and placing a huge demand on their cardiorespiratory system (Joyner & Coyle 2008). To define and classify athletes, it has been proposed that competitive athletes exercise for 6 h or more per week and recreational athletes for at least 3 h; although endurance runners and cyclists often train equal volumes to professional athletes (Pelliccia et al. 2021). Running is a highly accessible and affordable sport attracting long-distance adult athletes predominantly at a recreational level (DeJong, Fish & Hertel 2021). Unlike elite athletes, they may lack access to sports medicine professionals who disseminate return to sport (RTS) guidelines and screen for the risk of cardiac involvement (Elliott et al. 2020). Published RTS criteria are primarily based on the presence and severity of symptoms (Steinacker et al. 2022). This leads to concerns about adult recreational athletes exercising while potentially still feeling unwell (Ruuskanen et al. 2022). There is a need for prolonged observation and follow-up of athletes who had COVID-19, particularly with cardiovascular sequelae (Monosilio et al. 2023).

Our study aims to compare acute and exertional symptoms, fatigue, and exercise performance experienced by masters age group endurance athletes who had returned to their previous level of sport to those who had not. The results of our study may provide valuable insights for healthcare professionals, coaches, and athletes alike to understand variables associated with protracted RTS after COVID-19. This will facilitate better outcomes after respiratory tract infections and more effective management of RTS and expectations of competitive and recreational endurance athletes after respiratory tract infections.

## Research methods and design

### Study design

Our study is a cross-sectional survey-based observational to determine the difference in demographic and sport-specific

characteristics, disease severity, duration, and symptoms, self-reported approach to RTS and exercise capacity, and fatigue score between athletes who had returned to their pre-illness level of sport and those who had not. The impetus for our study was the threat of COVID-19 consequences in athletes over the age of 35 years, doing a high volume of cardiovascular exercise. Participants were recruited by snowball sampling from athletic clubs in South Africa between December 2021 and July 2022. Emailers were sent to 64 athletic clubs containing the invitation to participate in the online survey and a request to forward it on to their members. The invitation was also disseminated via social media to 18 WhatsApp groups and 25 Facebook pages. Athletic clubs approved the post on their social media pages and chats. Invitations could then be forwarded by the recipients in a snowball fashion to fellow athletes.

### Study population and sampling strategy

Eligible participants were adult (age 18+) endurance athletes of both sexes who ran for three or more hours per week or cycled for three or more hours per week (McKinney et al. 2019). Those who participated in additional sports over and above were also included and described as multisport athletes. The athletes had either been diagnosed with COVID-19 through a positive polymerase chain reaction (PCR) test or exhibited the known symptoms of COVID-19. Athletes who were admitted to the intensive care unit (ICU) were excluded as ICU-acquired weakness occurs from 15–29 days, and necessitates prolonged rehabilitation to return to normal function (Van Aerde et al. 2020). Other exclusion criteria for athletes were not being proficient in the English language, residing outside of South Africa, and a lack of informed consent. The sample size estimation equalled 178. This was based on the change in aerobic capacity of the athletic population infected with COVID-19 compared to a control group (10.0% vs. 3.5%) (Crameri et al. 2020), with an effect size of 0.63, a confidence interval (CI) of 0.05, power of 0.9, and adding 10% for each confounding variable that is age, sex, sport, stage of disease. To achieve this sample size, we assumed a 30% response rate and 50 members per athletics club. At the time, the prevalence of COVID-19 infections in the city was 5.4%, thus, the questionnaire needed to be accessed by 3200 athletes at 64 clubs.

### Data collection

A self-administered web-based questionnaire was developed by the research team using the Research Electronic Data Capture (REDCap) platform and was based on current literature. Sociodemographic data including sex, age, and sport-specific data constituted the first 10 questions, followed by 10 questions on COVID-19 status, prevalence of comorbidities, and post-COVID sequelae. The third section included questions regarding the management of their acute illness based on the World Health Organization (WHO) Severity Scale (Marshall et al. 2020) and symptoms classified according to the National Institutes of Health (NIH) clinical



spectrum (COVID-19 Treatment Guidelines, 2023). Symptom duration and time to return to their pre-illness level of sport were categorised to align with the NICE definitions (NICE 2021). The change in exercise tolerance was based on self-reported pace and power values.

Fatigue was scored using the standardised Multidimensional Fatigue Inventory (MDFI) tool (Smets et al. 1995). The MDFI consists of 20 questions that assess five categories of fatigue, namely: general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. The scales used are freely available, thus no permissions were required. The MDFI has good internal consistency (Cronbach's  $\alpha = 0.84$ ), and construct and convergent validity are reported (Smets et al. 1995). A professional panel in the field of sports medicine and respiratory health validated our study questionnaire. Construct validity of the questionnaire as a research tool was performed by sending a test questionnaire to 10 COVID-19 convalescent athletes, 4 of whom were medical professionals. Test-retest reliability was performed 2 weeks apart to avoid a learning effect. The null hypothesis of this study was that there was no difference in the effect of COVID-19 on the group that had returned to their pre-illness level of sports participation (y-RTS) versus those that had not (n-RTS). The primary outcome was a return to the pre-illness level of sport. Therefore, in the statistical analysis, we abbreviated the subgroup of athletes who selected the option 'still not returned to pre-illness level of sport' in the questionnaire as the n-RTS group. All others were combined into the y-RTS group.

## Data analysis

A lack of consent, answering 'No' to contracting COVID-19, or incomplete symptom data resulted in exclusion from data analysis. There was minimal missing data as radio button questions were marked \*required. Data were extracted from REDCap into Microsoft Excel and imported into SPSS Statistics for Mac 28.0.1.1.(14) (IBM, Chicago, IL, United States [US]), which was used for all analyses. Descriptive characteristics were calculated using means and standard deviations for continuous variables, and percentages and frequencies for categorical variables for the total sample (All), the group that had returned to pre-illness level of sport (y-RTS), and the group that had not (n-RTS). The normality of distribution of continuous variables was assessed with the Shapiro–Wilk test. Independent t-tests were used to compare normally distributed variables and Mann–Whitney U test for parametric continuous data. Chi-square or Fisher's exact tests were used to compare categorical data, with Cochran trend for 'symptom duration'. Univariate and multivariate logistic regression was performed to evaluate the risk of not returning to pre-illness level of sport associated with the following variables: sex, age, general fatigue, physical fatigue, reduced activity, mental fatigue, reduced motivation, and exertional dyspnoea. Because of a strong association of general fatigue, physical fatigue and dyspnoea, only physical fatigue was included in the multivariate model.

Model assumptions including goodness of fit, removal of residuals and collinearity were met.


## Ethical considerations

Unconditional ethical approval was provided by the University of the Witwatersrand's Human Research Ethics Committee (Medical) (Certificate no. M210657). Our study procedures adhered to the principles set forth in the Declaration of Helsinki and the South African Guidelines for Good Clinical Practice and the Medical Research Council. An information sheet explaining our study purpose and data sharing according to the FAIR principles (GO FAIR, FAIR principles 2016) was linked to the survey and ensured confidentiality and anonymity and permission to withdraw from our study at any point. The participants were asked if they consented to the anonymised data being used for research purposes. After electronic consent was obtained, the full questionnaire opened. The completion of the questions implied that consent was given throughout. Only the research team had access to the REDCap platform on which the information sheet and survey was developed and data were stored. The exported data were stored one password-protected computer and backed up to Apple iCloud Drive.

## Results

### Demographic, sport-specific, and return to pre-illness level of sport characteristics of our study population

After the surveys were assessed for eligibility, 308 participants were included in data analysis (Figure 1). Table 1 summarises our study population characteristics in three groups: all 308 participants, 211 (68.5%) who returned to pre-illness level of sport (y-RTS), and 97 (31.5%) who had not yet returned (n-RTS). The mean age was  $44.9 \pm 10.2$  years, and 170 (55.2%) were male. There is no significant



COVID-19, coronavirus disease 2019; FB, Facebook; RTS, return to sport.

**FIGURE 1:** Study sample selection process.



**TABLE 1:** Demographic, sport-specific and coronavirus disease 2019 characteristics of our study population.

| Variable                                          | All ( <i>N</i> = 308) |      | y-RTS ( <i>n</i> = 211) |      | n-RTS ( <i>n</i> = 97) |      | <i>p</i> |
|---------------------------------------------------|-----------------------|------|-------------------------|------|------------------------|------|----------|
|                                                   | <i>n</i>              | %    | <i>n</i>                | %    | <i>n</i>               | %    |          |
| <b>Sex</b>                                        | -                     | -    | -                       | -    | -                      | -    | 0.531    |
| Male                                              | 170                   | 55.2 | 119                     | 56.4 | 51                     | 52.6 | -        |
| Female                                            | 138                   | 44.8 | 92                      | 43.6 | 46                     | 47.4 | -        |
| <b>Age groups (years)</b>                         | -                     | -    | -                       | -    | -                      | -    | 0.417    |
| 18–29                                             | 22                    | 7.1  | 18                      | 8.5  | 4                      | 4.1  | -        |
| 30–39                                             | 70                    | 22.7 | 43                      | 20.4 | 27                     | 27.8 | -        |
| 40–49                                             | 115                   | 37.4 | 82                      | 38.9 | 33                     | 34.0 | -        |
| 50–59                                             | 80                    | 26.0 | 54                      | 25.6 | 26                     | 26.8 | -        |
| 60–71                                             | 21                    | 6.8  | 14                      | 6.6  | 7                      | 7.2  | -        |
| <b>Type of sport†</b>                             | -                     | -    | -                       | -    | -                      | -    | 0.598    |
| Running                                           | 122                   | 39.6 | 85                      | 40.3 | 37                     | 38.1 | -        |
| Cycling                                           | 55                    | 17.9 | 40                      | 19.0 | 15                     | 15.5 | -        |
| Multisport                                        | 124                   | 40.3 | 81                      | 38.4 | 43                     | 44.3 | -        |
| <b>Level of participation</b>                     | -                     | -    | -                       | -    | -                      | -    | 0.506    |
| Elite                                             | 16                    | 5.2  | 13                      | 6.2  | 3                      | 3.1  | -        |
| Competitive                                       | 99                    | 32.1 | 66                      | 31.3 | 33                     | 34.0 | -        |
| Recreational                                      | 193                   | 62.7 | 132                     | 62.6 | 61                     | 62.9 | -        |
| <b>Pre-COVID training volume (hours per week)</b> | -                     | -    | -                       | -    | -                      | -    | 0.503    |
| < 6                                               | 84                    | 30.3 | 63                      | 29.8 | 21                     | 21.7 | -        |
| ≥ 6                                               | 224                   | 72.7 | 148                     | 70.1 | 76                     | 78.4 | -        |
| <b>Comorbidities</b>                              | -                     | -    | -                       | -    | -                      | -    | 0.672    |
| Yes                                               | 55                    | 17.9 | 39                      | 18.5 | 16                     | 16.5 | -        |
| No                                                | 253                   | 82.1 | 172                     | 81.5 | 81                     | 83.5 | -        |
| <b>Deteriorated pre-existing co-morbidities</b>   | -                     | -    | -                       | -    | -                      | -    | 0.189    |
| Yes                                               | 14                    | 4.5  | 8                       | 3.8  | 6                      | 6.2  | -        |
| No                                                | 41                    | 13.3 | 31                      | 14.7 | 10                     | 10.3 | -        |
| <b>Time from the onset of COVID-19 to study‡</b>  | -                     | -    | -                       | -    | -                      | -    | 0.151    |
| ≤ 3 weeks                                         | 36                    | 11.7 | 25                      | 11.8 | 11                     | 11.3 | -        |
| 4–8 weeks                                         | 54                    | 17.5 | 30                      | 14.2 | 24                     | 24.7 | -        |
| 3–6 months                                        | 87                    | 28.2 | 61                      | 28.9 | 26                     | 26.8 | -        |
| > 7 months                                        | 131                   | 42.5 | 95                      | 45.0 | 36                     | 37.1 | -        |
| <b>Treatment WHO severity§</b>                    | -                     | -    | -                       | -    | -                      | -    | 0.032    |
| 0–2                                               | 158                   | 51.3 | 117                     | 55.5 | 41                     | 42.3 | -        |
| 3                                                 | 150                   | 48.7 | 94                      | 44.5 | 56                     | 57.7 | -        |

COVID-19, coronavirus disease 2019; n-RTS, not returned to pre-illness level of sport; WHO, World Health Organization; y-RTS, returned to pre-illness level of sport.

†, type of sport was divided into 'running' = running only, 'cycling' = cycling only, and 'multisport' = additional sports including running or cycling.

‡, we assume variant based on the elapsed time since onset of illness: omicron < 8 weeks, beta 3–6 months, delta > 7 months.

§, World Health Organization COVID-19 Severity Scale: 0–2 = No treatment or did not consult a healthcare professional, 3 = Consulted a healthcare professional or admitted to hospital.

difference in the demographic and sport-specific characteristics of y-RTS versus n-RTS.

Most athletes did not have coexisting comorbidities (*n* = 253, 82.1%). However, comorbidities that were reported include asthma (*n* = 18, 5.8%), hypertension (*n* = 12, 3.8%), and cardiac disease (*n* = 4, 1.3%). The majority (94%) of athletes (*n* = 289) experienced one or more of the known COVID-19 symptoms. The only significant difference in COVID-19 characteristics of the y-RTS group compared to the n-RTS was the severity of the disease according to the WHO COVID-19 Severity Scale, indicating that more athletes consulted healthcare professionals and/or were admitted to hospital in the n-RTS group (*p* = 0.032).

### Acute and subacute symptoms

Table 2 summarises symptoms at the time of illness. There was no significant difference in asymptomatic disease experienced by the y-RTS versus n-RTS groups. A total of 21 participants (6.8%) tested negative, but their symptom presentation implied

false negative tests. Fatigue was the only mild symptom more prevalent in the n-RTS group (*p* = 0.044). We found a higher proportion of moderate disease in n-RTS group (*p* = 0.006). There were eight athletes in total with severe illness requiring supplemental oxygen, with no significant difference between the groups (*p* = 0.710). No participants cited critical illness. Post-COVID-19 sequelae included cardiac (*n* = 15, 4.9%) and pulmonary (*n* = 12, 3.9%) consequences, and were more prevalent in the n-RTS group (*p* = 0.031).

### Factors associated with return to pre-illness level of sport

The time frame in which athletes in the whole group returned to pre-illness level of sport is displayed in Figure 2, with *n* = 97 (31.5%) not yet at their previous level and constituted the n-RTS group. Table 3 displays the presence and severity of symptoms while exercising and other self-reported factors limiting their RTS. The athletes approached their resumption of training with similar consideration of most factors, with only pace being monitored more closely in the n-RTS group




**TABLE 2:** Coronavirus disease 2019 symptoms experienced at the time of illness.

| Variable                       | All (N = 308) |      | y-RTS (n = 211, 68.5%) |      | n-RTS (n = 97, 31.5%) |      | p     |
|--------------------------------|---------------|------|------------------------|------|-----------------------|------|-------|
|                                | n             | %    | n                      | %    | n                     | %    |       |
| COVID-19                       | -             | -    | -                      | -    | -                     | -    | 0.201 |
| symptoms                       | 289           | 93.8 | 195                    | 92.4 | 94                    | 96.9 | -     |
| asymptomatic                   | 19            | 6.2  | 16                     | 7.6  | 3                     | 3.1  | -     |
| <b>Acute symptoms†</b>         |               |      |                        |      |                       |      |       |
| Mild:                          |               |      |                        |      |                       |      |       |
| Malaise or Fatigue             | 184           | 59.7 | 118                    | 55.9 | 66                    | 68.0 | 0.044 |
| Headache                       | 139           | 45.1 | 92                     | 43.6 | 47                    | 48.5 | 0.427 |
| Myalgia                        | 133           | 43.2 | 85                     | 40.3 | 48                    | 49.5 | 0.130 |
| Ageusia or anosmia             | 84            | 27.3 | 56                     | 26.5 | 41                    | 42.3 | 0.670 |
| Cough                          | 83            | 26.9 | 51                     | 24.2 | 32                    | 33.0 | 0.105 |
| Fever                          | 63            | 20.5 | 42                     | 19.9 | 21                    | 21.6 | 0.724 |
| Diarrhoea                      | 21            | 21.6 | 9                      | 4.3  | 3                     | 3.1  | 0.445 |
| Moderate:                      |               |      |                        |      |                       |      |       |
| Dyspnoea SpO <sub>2</sub> ≥ 94 | 97            | 31.5 | 56                     | 26.5 | 41                    | 42.3 | 0.006 |
| Severe:                        |               |      |                        |      |                       |      |       |
| Dyspnoea SpO <sub>2</sub> ≤ 94 | 8             | 2.6  | 5                      | 2.4  | 3                     | 3.1  | 0.710 |
| Symptom duration (weeks)       | -             | -    | -                      | -    | -                     | -    | 0.009 |
| < 1                            | 83            | 26.9 | 68                     | 32.2 | 15                    | 15.5 | -     |
| 1–2                            | 118           | 38.3 | 83                     | 39.3 | 35                    | 36.1 | -     |
| 3–4                            | 51            | 16.6 | 7                      | 12.8 | 24                    | 24.7 | -     |
| 5–8                            | 28            | 9.1  | 15                     | 7.1  | 13                    | 13.4 | -     |
| > 8                            | 28            | 9.1  | 18                     | 8.5  | 10                    | 10.3 | -     |
| Post-COVID-19 sequelae         | 44            | 14.3 | 24                     | 11.4 | 20                    | 20.6 | 0.031 |

COVID-19, coronavirus disease 2019; n-RTS, not returned to pre-illness level of sport; WHO, World Health Organization; y-RTS, returned to pre-illness level of sport.

†. Multiple responses were allowed in the survey, resulting in cumulative percentages exceeding 100%. Symptoms are classified as mild, moderate, or severe illness according to the National Institute of Health (COVID-19 Treatment Guidelines).



RTS, return to sport.

**FIGURE 2:** Time to return to pre-illness sport for our study population (n = 308).

( $p = 0.035$ ). There was a distinctly higher proportion ( $n = 27$ , 27.8%) of athletes still experiencing symptoms at rest in the n-RTS group. The most frequently reported exertional symptoms by the whole group were fatigue ( $n = 216$ , 70.1%), and elevated heart rate ( $n = 216$ , 70.1%), followed by dyspnoea ( $n = 174$ , 56.5%). All symptoms except musculoskeletal pain occurred significantly more frequently in the n-RTS group. All self-reported limitations to exercise capacity were more common in the n-RTS group ( $p < 0.001$ ). Training volume ( $p < 0.001$ ), running pace ( $p < 0.001$ ), and cycling threshold power ( $p = 0.024$ ) were lower in the n-RTS group compared to the y-RTS group.

### Fatigue and the endurance athlete

The MDFI (Table 4) assesses five categories of fatigue (general fatigue, physical fatigue, reduced activity, reduced

motivation and mental fatigue). Athletes who had not yet returned to pre-illness level scored higher in all fatigue categories, indicating considerably worse overall fatigue compared to the y-RTS group ( $p < 0.001$ ). The results of the univariate regression analysis in Table 5 suggest all variables excluding age and sex are associated with RTS. The multivariate regression analysis adjusted for dyspnoea and general fatigue, showed that an increase in physical fatigue is associated with decreased odds of return to sport (OR 0.673,  $p < 0.001$ ). An increase in mental fatigue is associated with increased odds of return to sport (OR 1.0361,  $p = 0.047$ ).

## Discussion

Our study provides insight into acute and exertional symptoms associated with protracted exercise tolerance in a masters-age athlete population that does a high volume of cardiovascular exercise yet has had little investigation. Following several studies earlier in the pandemic that focussed on elite team sport athletes (Petek et al. 2021), our study included a large sample of endurance athletes, closely matching the demographics of marathon runners worldwide. Because of a global shortage of polymerase chain reaction (PCR) tests in 2020, and the questionable reliability thereof (Burgstahler et al. 2023), many diagnoses were based on symptom presentation or positive contact. Therefore, studies such as ours included symptomatic individuals who may not have been tested or had either a positive or negative PCR test result. Our findings suggest that acute fatigue, longer symptom duration, post-COVID-19 sequelae, exertional symptoms especially



**TABLE 3:** The athlete's approach to return to sport, the presence of exertional symptoms, challenges, and exercise capacity.

| Variable                                                 | All (N = 308) |      |        |            | y-RTS (n = 211, 68.5%) |      |        |             | n-RTS (n = 97, 31.5%) |      |        |             | p       |
|----------------------------------------------------------|---------------|------|--------|------------|------------------------|------|--------|-------------|-----------------------|------|--------|-------------|---------|
|                                                          | n             | %    | Median | 95% CI     | n                      | %    | Median | 95% CI      | n                     | %    | Median | 95% CI      |         |
| <b>Received RTS guidelines</b>                           | -             | -    | -      | -          | -                      | -    | -      | -           | -                     | -    | -      | -           | 0.853   |
| Yes                                                      | 121           | 39.3 | -      | -          | 83                     | 39.3 | -      | -           | 38                    | 39.2 | -      | -           | -       |
| No                                                       | 187           | 60.7 | -      | -          | 128                    | 60.7 | -      | -           | 59                    | 60.8 | -      | -           | -       |
| <b>Symptoms at rest</b>                                  | -             | -    | -      | -          | -                      | -    | -      | -           | -                     | -    | -      | -           | 0.005   |
| Yes                                                      | 56            | 18.2 | -      | -          | 29                     | 13.7 | -      | -           | 27                    | 27.8 | -      | -           | -       |
| No                                                       | 252           | 81.8 | -      | -          | 182                    | 86.3 | -      | -           | 70                    | 72.2 | -      | -           | -       |
| <b>Monitoring during RTS</b>                             |               |      |        |            |                        |      |        |             |                       |      |        |             |         |
| Resting, average, and maximal heart rate                 | 215           | 69.8 | -      | -          | 143                    | 67.8 | -      | -           | 72                    | 74.2 | -      | -           | 0.252   |
| Pace or speed                                            | 186           | 60.4 | -      | -          | 119                    | 56.4 | -      | -           | 67                    | 69.1 | -      | -           | 0.035   |
| Rate of perceived exertion                               | 100           | 32.5 | -      | -          | 71                     | 33.6 | -      | -           | 29                    | 29.9 | -      | -           | 0.514   |
| Sleep quality                                            | 103           | 33.4 | -      | -          | 68                     | 32.2 | -      | -           | 35                    | 36.1 | -      | -           | 0.505   |
| Stress                                                   | 52            | 16.9 | -      | -          | 38                     | 18.0 | -      | -           | 14                    | 14.4 | -      | -           | 0.539   |
| Fatigue                                                  | 121           | 39.3 | -      | -          | 78                     | 37.0 | -      | -           | 43                    | 44.3 | -      | -           | 0.219   |
| Myalgia                                                  | 103           | 33.4 | -      | -          | 70                     | 33.2 | -      | -           | 33                    | 34.0 | -      | -           | 0.884   |
| <b>Presence of symptoms while exercising†</b>            |               |      |        |            |                        |      |        |             |                       |      |        |             |         |
| Fatigue                                                  | 216           | 70.1 | -      | -          | 134                    | 63.4 | -      | -           | 82                    | 84.6 | -      | -           | < 0.001 |
| Post-exertional malaise                                  | 183           | 59.4 | -      | -          | 105                    | 49.8 | -      | -           | 78                    | 80.4 | -      | -           | < 0.001 |
| Headache                                                 | 105           | 34.2 | -      | -          | 61                     | 29.0 | -      | -           | 44                    | 45.4 | -      | -           | 0.005   |
| Musculoskeletal pain                                     | 189           | 61.4 | -      | -          | 126                    | 59.7 | -      | -           | 63                    | 64.9 | -      | -           | 0.381   |
| Autonomic disturbance including POTS‡                    | 132           | 42.9 | -      | -          | 74                     | 35.0 | -      | -           | 58                    | 59.7 | -      | -           | < 0.001 |
| Elevated heart rate                                      | 216           | 70.0 | -      | -          | 131                    | 62.1 | -      | -           | 85                    | 87.6 | -      | -           | < 0.001 |
| Dyspnoea                                                 | 174           | 56.5 | -      | -          | 104                    | 49.3 | -      | -           | 70                    | 72.2 | -      | -           | < 0.001 |
| Chest pain                                               | 64            | 20.7 | -      | -          | 30                     | 14.2 | -      | -           | 34                    | 35.0 | -      | -           | < 0.001 |
| <b>Self-reported factors limiting exercise tolerance</b> |               |      |        |            |                        |      |        |             |                       |      |        |             |         |
| Poor endurance                                           | 199           | 64.6 | -      | -          | 108                    | 51.2 | -      | -           | 91                    | 93.8 | -      | -           | < 0.001 |
| Poor peak power                                          | 223           | 72.4 | -      | -          | 129                    | 61.1 | -      | -           | 94                    | 96.8 | -      | -           | < 0.001 |
| Difficulty hill climbing                                 | 220           | 71.4 | -      | -          | 133                    | 63.0 | -      | -           | 87                    | 89.7 | -      | -           | < 0.001 |
| Long-COVID-19 concerns                                   | 184           | 59.8 | -      | -          | 104                    | 49.3 | -      | -           | 80                    | 82.5 | -      | -           | < 0.001 |
| Anxiety or depression                                    | 147           | 47.7 | -      | -          | 82                     | 38.9 | -      | -           | 65                    | 67.0 | -      | -           | < 0.001 |
| Training volume pre-post§ (hours per week)               | 308           | -    | 0.5    | 0.97–1.69  | 211                    | -    | 0.0    | 0.24–1.07   | 97                    | -    | 3.0    | 2.19–3.40   | < 0.001 |
| Running pace pre-post (min.km <sup>-1</sup> )            | 244           | -    | 0.0    | 0.54–0.80  | 164                    | -    | 0.0    | 0.19–0.46   | 80                    | -    | 1.0    | 1.18–1.66   | < 0.001 |
| FTP pre-post (W.kg <sup>-1</sup> )                       | 60            | -    | 17.0   | 7.55–29.06 | 46                     | -    | 8.0    | -4.62–22.68 | 14                    | -    | 30.0   | 17.53–61.87 | 0.024   |

CI, confidence interval; COVID-19, coronavirus disease 2019; FTP, Functional threshold power; n-RTS, not returned to pre-illness level of sport; RTS, return to sport; POTS, postural orthostatic tachycardia syndrome; y-RTS, returned to pre-illness level of sport.

†, Multiple responses were allowed in the survey, resulting in cumulative percentages exceeding 100%. Symptoms are classified as mild, moderate, or severe illness according to the National Institute of Health (COVID-19 Treatment Guidelines).

‡, Data can fall in more than one category.

§, Pre-post: Pre-COVID-19 minus post-COVID-19.

**TABLE 4:** Multidimensional fatigue inventory scores.

| Variable           | All (N = 308)<br>Mean ± s.d. | y-RTS (n = 211)<br>Mean ± s.d. | n-RTS (n = 97)<br>Mean ± s.d. | p       |
|--------------------|------------------------------|--------------------------------|-------------------------------|---------|
| General fatigue    | 11.04 ± 3.99                 | 9.70 ± 3.57                    | 13.89 ± 3.28                  | < 0.001 |
| Physical fatigue   | 9.48 ± 4.12                  | 7.93 ± 3.49                    | 12.79 ± 3.33                  | < 0.001 |
| Reduced activity   | 8.36 ± 3.41                  | 7.29 ± 2.86                    | 10.63 ± 3.38                  | < 0.001 |
| Reduced motivation | 8.48 ± 3.45                  | 7.58 ± 3.12                    | 10.40 ± 3.34                  | < 0.001 |
| Mental fatigue     | 10.11 ± 4.06                 | 9.51 ± 4.06                    | 11.37 ± 3.77                  | < 0.001 |
| MDFI Total         | 47.44 ± 16.33                | 41.99 ± 14.40                  | 59.08 ± 13.98                 | < 0.001 |

MDFI, multidimensional fatigue inventory; n-RTS, not returned to pre-illness level of sport; y-RTS, returned to pre-illness level of sport.

dyspnoea, and chronic physical fatigue are associated with protracted RTS in endurance athletes.

Nearly one third of the athletes had not yet returned to pre-illness levels at the time of data collection. Many (27.8%) were still experiencing symptoms at rest, potentially explaining the less than 6-h per week training volume typical

of recreational endurance athletes (McKinney et al. 2019). The most frequently reported acute symptoms in our study (fatigue, headache, and myalgia) were consistent with the findings of other studies (Lopes et al. 2021; Magnusson et al. 2022; Sewry et al. 2022), yet only fatigue was associated with protracted RTS in our study. Athletes have missed training more often because of fatigue after COVID-19 than any other viral illnesses or symptoms (Schwellnus et al. 2021).

The presence of exertional symptoms is widely documented, suggesting that athletes begin training while feeling unwell (Schroeder et al. 2023). Our study confirmed this, as 70% of the entire group experienced fatigue or elevated heart rate while exercising, 57% experienced dyspnoea, and 21% experienced chest pain. Hughes et al. (2022) proposed no exercise resumption until symptoms had abated or diminished. Whether the 35% of the n-RTS group who experienced chest pain followed RTS guidelines and thereby



**TABLE 5:** Univariate and multivariate logistic regression analysis to determine the likelihood of variables explaining the variation in return to sport.

| Variable           | Univariate logistic regression |             |         | Multivariate logistic regression† |             |         |
|--------------------|--------------------------------|-------------|---------|-----------------------------------|-------------|---------|
|                    | OR                             | 95% CI      | p       | OR                                | 95% CI      | p       |
| Age                | 0.995                          | 0.971–1.019 | 0.672   | 1.019                             | 0.988–1.052 | 0.222   |
| Sex                | 0.857                          | 0.529–1.389 | 0.531   | 1.311                             | 0.696–2.470 | 0.402   |
| General fatigue    | 0.781                          | 0.659–0.783 | < 0.001 | -                                 | -           | -       |
| Physical fatigue   | 0.702                          | 0.645–0.764 | < 0.001 | 0.673                             | 0.592–0.766 | < 0.001 |
| Reduced activity   | 0.724                          | 0.662–0.791 | < 0.001 | 0.884                             | 0.756–1.034 | 0.123   |
| Mental fatigue     | 0.891                          | 0.837–0.948 | < 0.001 | 1.036                             | 1.001–1.223 | 0.047   |
| Reduced motivation | 0.777                          | 0.781–0.841 | < 0.001 | 1.107                             | 0.898–1.194 | 0.632   |
| Dyspnoea           | 0.375                          | 0.223–0.630 | < 0.001 | -                                 | -           | -       |

OR, odds ratio; CI, confidence interval.

†, Hosmer and Lemeshow goodness-of-fit test  $p = 0.495$ .

reduced their training is unknown, as 14% of the y-RTS group also reported chest pain. Although the reasons why the athletes did not return to pre-illness level was not specifically investigated, the results suggest that persistent symptoms interfered with full athletic performance.

In our study, athletes with post-COVID-19 sequelae were less likely to return to their previous performance levels, consistent with Schroeder et al. (2023). Our study found a higher prevalence of cardiovascular sequelae (8.8%) compared to those reviewed by Monosilio et al. (2023), probably because of this study's higher average age. Herein lies an important finding. Myocarditis, arrhythmias and other cardiopulmonary post-COVID-19 sequelae presented in our study, are a concern and may be underreported in masters age-group athletes. Ventricular arrhythmias were found to occur in asymptomatic or mild disease (Casasco et al. 2022), and these athletes, constituting the bulk of the field in marathons events, may not have undergone routine cardiac screening. Our findings imply that older athletes and those with post-COVID-19 sequelae require better management. These athletes should monitor resting and exertional heart rate, sleep quality, cardiopulmonary symptoms, and fatigue after resuming exercise (Steinacker et al. 2022). While the athletes in our study were adept at monitoring heart rate and pace facilitated by popular wearable devices, it is recommended that athletes be more aware of the symptoms they experience and the implications thereof on RTS.

A novel finding in our study was the significantly decreased odds of RTS in those with physical fatigue, while mental fatigue is strongly associated with increased odds of RTS. This may seem counterintuitive as fatigue and impaired neurocognitive ability can lead to protracted exercise tolerance (Steinacker et al. 2022). Mental fatigue often occurs because of a prolonged period of demanding cognitive tasks yet may also develop from the frustration of trying harder to resume fitness compared to other respiratory illnesses (Marcora et al. 2009). In a scoping review by Oswald et al. (2020), running has been unequivocally positively associated with improving mood, sense of well-being, self-efficacy, and decreased depression. Regular runners who were prevented from running for 2 weeks had increased anxiety and depression compared to the runners who continued (Oswald et al. 2020). Hence, an unexpected finding becomes expected.

This relationship may further explain the tendency for endurance athletes to resume training before recovering sufficiently.

Our study is one of the first to compare individuals who successfully rebuilt their pre-illness fitness level to those who were still struggling. Our results suggest that the n-RTS group intentionally reduced the intensity of their training during recovery. Post-COVID-19 performance capacity as determined by training volume, running speed, and cycling threshold power was lower in the n-RTS group when compared to pre-COVID-19 levels. In contrast, Emeran et al. (2022) found no difference in running speed or training volume. A large proportion of athletes did not return to sport after having moderate illness, likely because of the symptom severity directly precluding RTS, or recommendations from healthcare providers (Schroeder et al. 2023), as more consultations were attended by athletes in the n-RTS group. Longer symptom duration, and especially persistent fatigue was more prevalent in the n-RTS group, which can negatively affect quality of life (Vollrath et al. 2022). As research investigating long-term consequences of COVID-19 on cardiorespiratory fitness and sports participation emerges, the knowledge gained needs to be disseminated to athletes, coaches, and medical professionals.

## Strengths and limitations

The main strength of this study is the sample size and statistical power. Athletes were recruited throughout South Africa, which enhances generalisability to the South African athletic population, although generalisation may not be translated to other countries. The focus of our study was endurance athletes and therefore mostly older than 35 years of age, fulfilling a gap in the literature. Quantifying subjective descriptions of fatigue by using the MDFI is a strength of our study as to our knowledge, it has not been used in other studies on athletic populations. Future studies using the MDFI in athletes is recommended. This is one of few studies that has associated exertional symptoms with RTS status.

As is customary for surveys, certain limitations exist. Snowball sampling will not allow a response rate to be calculated and recorded, thus reducing the power of our study. The participant's responses rely on retrospective recall



(recall bias) and the period from illness to the time of our study will vary between participants. The inclusion criteria did not specify the presence of COVID-19 symptoms, thus selection bias caused underrepresentation of the number of asymptomatic cases. Vaccine status was unknown; however, by deducing from the time of illness, most athletes would not have had the opportunity to be vaccinated. Athletes in our study would have been infected by a mix of viral strains. We did not ask whether home oxygen was used, which may have placed some participants not admitted to the hospital in the 'severe illness' category. These limitations were unavoidable with the current knowledge at the time of our study. No direct cause-effect relationship can be determined from our observational study.

## Interpretation

These findings may provide valuable insights into the acute and long-term manifestations of this disease in a masters-age athlete population. Symptoms that may indicate cardiopulmonary consequences in an athlete population that does a high volume of cardiovascular exercise should be investigated. An interdisciplinary approach to management is vital to facilitate return to sport and the important mental and physical benefits thereof. This will augment outcomes after respiratory tract infections in endurance athletes.

## Conclusion

Our findings suggest that acute fatigue, longer symptom duration, post-COVID sequelae, the presence of exertional symptoms particularly dyspnoea, and chronic physical fatigue are associated with protracted RTS in endurance athletes. These symptoms still abound albeit less frequently after infection by the current Omicron variant. Such symptoms should continue to be flagged and managed to prevent protracted RTS, with further investigations if cardiopulmonary consequences are suspected. Consideration of the mental gains of physical activity ought to be given high regard while building the endurance athlete's training load to return to their pre-illness level.

## Acknowledgements

This article is a partial contribution to the author's thesis entitled 'The impact of COVID-19 on endurance athletes' return to pre-illness level of participation' toward the degree of Doctor of Philosophy in Physiotherapy in the Physiotherapy Department, University of the Witwatersrand, South Africa, with supervisors Prof Heleen van Aswegen and Prof Benita Olivier. The thesis has not been published at the time of publication.

## Competing interests

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

## Authors' contributions

C.A.H., H.v.A., B.O. contributed to the study design. C.A.H. collected the data. C.A.H. and E.L. performed the statistical analysis. C.A.H. wrote the original draft of the article. C.A.H., H.v.A., B.O. and E.L. contributed to the editing and revision of the article.

## Funding information

The authors received no financial support for the research, authorship, and/or publication of this article.

## Data availability

Data will be made available upon request and after considering the intentions of use, ethical clearance, and appropriateness of available data. The corresponding author, C.H., may be contacted in this regard.

## Disclaimer

The views and opinions expressed in this article are those of the authors and are the product of professional research. They do not necessarily reflect the official policy or position of any affiliated institution, funder, agency, or that of the publisher. The authors are responsible for this article's results, findings, and content.

## References

- Agha-Alinejad, H., Ahmadi Hekmatikar, A.H., Ruhee, R.T., Shamsi, M.M., Rahmati, M., Khoramipour, K. et al., 2022, 'A guide to different intensities of exercise, vaccination, and sports nutrition in the course of preparing elite athletes for the management of upper respiratory infections during the COVID-19 pandemic: A narrative review', *International Journal of Environmental Research and Public Health* 19(3), 1888. <https://doi.org/10.3390/ijerph19031888>
- Braga, F., Domecq, F., Kalichsstein, M., Nobre, G., Kezen, J., Espinosa, G. et al., 2023, 'Abnormal exercise adaptation after varying severities of COVID-19: A controlled cross-sectional analysis of 392 survivors', *European Journal of Sport Science* 23(5), 829–839. <https://doi.org/10.1080/17461391.2022.2054363>
- Burgstahler, C., Plank, C., Niess, A.M., Schobersberger, W., Niebauer, J. & Scharhag, J., 2023, 'Effects of the corona pandemic on competitive sports – An online survey amongst 2981 German and Austrian elite athletes', *German Journal of Sports Medicine/Deutsche Zeitschrift für Sportmedizin* 74(1), 7–12. <https://doi.org/10.5960/dzsm.2022.552>
- Casasco, M., Iellamo, F., Scorcu, M., Parisi, A., Tavcar, I., Bruglin, E. et al., 2022, 'Return to play after SARS-CoV-2 infection in competitive athletes of distinct sport disciplines in Italy: A FMSI (Italian Federation of Sports Medicine) study', *Journal of Cardiovascular Development and Disease* 9(2), 59. <https://doi.org/10.3390/jcdd9020059>
- Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y. et al., 2020, 'Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study', *The Lancet* 395(2), 507–513. [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)
- COVID-19 Treatment Guidelines 2023, NIH: *Clinical spectrum of SARS-CoV-2 infection*, viewed 13 February 2023, from <http://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum>.
- Cramer, G.A.G., Bielecki, M., Zust, R., Buehrer, T.W., Stanga Z. & Deuel, J.W., 2020, 'Reduced maximal aerobic capacity after COVID-19 in young adult recruits, Switzerland, May 2020', *Eurosurveillance. European Centre for Disease Prevention and Control (EDC)* 25(36), 2001542. <https://doi.org/10.2807/1560-7917.ES.2020.25.36.2001542>
- DeJong, A.F., Fish, P.N. & Hertel, J., 2021, 'Running behaviors, motivations, and injury risk during the COVID-19 pandemic: A survey of 1147 runners', *PloS One* 16(2), e0246300. <https://doi.org/10.1371/journal.pone.0246300>
- Durstenfeld, M.S., Sun, K., Tahir, P., Peluso, M.J., Deeks, S.G., Aras, M.A. et al., 2022, 'Use of cardiopulmonary exercise testing to evaluate long COVID-19 symptoms in adults: A systematic review and meta-analysis', *JAMA Network Open* 5(10), e2236057–e2236057. <https://doi.org/10.1001/jamanetworkopen.2022.36057>
- Elliott, N., Martin, R., Heron, N., Elliott, J., Grimstead, D. & Biswas, A., 2020, 'Infographic. Graduated return to play guidance following COVID-19 infection', *British Journal of Sports Medicine* 54(19), 1174–1175. <https://doi.org/10.1136/bjsports-2020-102637>



- Emeran, A., Lambert, E.V., Paruk, T. & Bosch, A., 2022, 'Changes in training activity post COVID-19 infection in recreational runners and cyclists', *South African Journal of Sports Medicine* 34(1), 1–7. <https://doi.org/10.17159/2078-516X/2022/v34i1a13758>
- Gluckman, T.J., Bhave, N.M., Allen, L.A., Chung, E.H., Spatz, E.S., Ammirati, E. et al., 2022, '2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults: Myocarditis and other myocardial involvement, post-acute sequelae of SARS-CoV-2 infection, and return to play: A report of the American College of Cardiology Solution Set Oversight Committee', *Journal of the American College of Cardiology* 79(17), 1717–1756. <https://doi.org/10.1016/j.jacc.2022.02.003>
- GO FAIR, FAIR principles, 2016, *GO FAIR*, viewed 13 May 2023, from <https://www.go-fair.org/fair-principles/>.
- Hughes, D.C., Orchard, J.W., Partridge, E.M., La Gerche, A. & Broderick, C., 2022, 'Return to exercise post-COVID-19 infection: A pragmatic approach in mid-2022', *Journal of Science and Medicine in Sport* 25(7), 544–547. <https://doi.org/10.1016/j.jsams.2022.06.001>
- Joyner, M.J. & Coyle, E.F., 2008, 'Endurance exercise performance: The physiology of champions', *The Journal of Physiology* 586(1), 35–44. <https://doi.org/10.1113/jphysiol.2007.143834>
- Juhász, V., Szabó, L., Pavlik, A., Tállay, A., Balla, D., Kiss, O. et al., 2022, 'Short and mid-term characteristics of COVID-19 disease course in athletes: A high-volume, single-center study', *Scandinavian Journal of Medicine & Science in Sports* 33(3), 341–352. <https://doi.org/10.1111/sms.14265>
- Lopes, L.R., Miranda, V.A., Goes, R.A., Souza, G.G., Souza, G.R., Rocha, J.C. et al., 2021, 'Repercussions of the COVID-19 pandemic on athletes: A cross-sectional study', *Biology of Sport* 38(4), 703–711. <https://doi.org/10.5114/biolsport.2021.106147>
- Magnusson, K., Kristoffersen, D.T., Dell'Isola, A., Kiadaliri, A., Turkiewicz, A., Runhaar, J. et al., 2022, 'Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants', *Nature Communications* 13(1), 7363. <https://doi.org/10.1038/s41467-022-35240-2>
- Marcora, S.M., Staiano, W. & Manning, V., 2009, 'Mental fatigue impairs physical performance in humans', *Journal of Applied Physiology* 106(3), 857–864. <https://doi.org/10.1152/jappphysiol.91324.2008>
- Marshall, J.C., Murthy, S., Diaz, J., Adhikari, N.K., Angus, D.C., Arabi, Y.M. et al., 2020, 'A minimal common outcome measure set for COVID-19 clinical research', *The Lancet Infectious Diseases* 20(8), e192–e197. [https://doi.org/10.1016/S1473-3099\(20\)30483-7](https://doi.org/10.1016/S1473-3099(20)30483-7)
- McKinney, J., Velghe, J., Fee, J., Isserow, S. & Drezner, J.A., 2019, 'Defining athletes and exercisers', *The American Journal of Cardiology* 123(3), 532–535. <https://doi.org/10.1016/j.amjcard.2018.11.001>
- Mihalick, V.L., Canada, J.M., Arena, R., Abbate, A. & Kirkman, D.L., 2021, 'Cardiopulmonary exercise testing during the COVID-19 pandemic', *Progress in Cardiovascular Diseases* 67, 35–39. <https://doi.org/10.1016/j.pcad.2021.04.005>
- Monosilio, S., Prosperi, S., Squeo, M.R., Spataro, S., Spataro, A. & Maestrini, V., 2023, 'Short and long-term cardiovascular sequelae after SARS-CoV-2 infection: A narrative review focusing on athletes', *Viruses* 15(2), 493. <https://doi.org/10.3390/v15020493>
- National Institute for Health and Care Excellence (NICE) SIGN (SIGN) and RC of GP (RCGP), 2021, *COVID-19 rapid guideline: Managing the long-term effects of COVID-19*, Updated November 2021, viewed 08 February 2023, from <https://www.nice.org.uk/guidance/ng188>.
- Oswald, F., Campbell, J., Williamson, C., Richards, J. & Kelly, P., 2020, 'A scoping review of the relationship between running and mental health', *International Journal of Environmental Research and Public Health* 17(21), 8059. <https://doi.org/10.3390/ijerph17218059>
- Pelliccia, A., Sharma, S., Gati, S., Bäck, M., Börjesson, M., Caselli, S. et al., 2021, '2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease: The task force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC)', *European Heart Journal* 42(1), 17–96. <https://doi.org/10.1093/eurheartj/ehaa605>
- Petek, B.J., Moulson, N., Baggish, A.L., Kliethermes, S.A., Patel, M.R., Churchill, T.W. et al., 2022, 'Prevalence and clinical implications of persistent or exertional cardiopulmonary symptoms following SARS-CoV-2 infection in 3597 collegiate athletes: A study from the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA)', *British Journal of Sports Medicine* 56(16), 913–918. <https://doi.org/10.1136/bjsports-2021-104644>
- Ruuskanen, O., Luoto, R., Valtonen, M., Heinonen, O.J. & Waris, M., 2022, 'Respiratory viral infections in athletes: Many unanswered questions', *Sports Medicine* 52(9), 2013–2021. <https://doi.org/10.1007/s40279-022-01660-9>
- Schroeder, A.N., Getzin, A.R., Creswell, L.L. & Asplund, C.A., 2023, 'Recovery from COVID-19 in adult recreational athletes: A survey of American triathletes', *Exercise, Sport, and Movement* 1(2), e00005. <https://doi.org/10.1249/ESM.0000000000000005>
- Schwellnus, M., Sewry, N., Snyders, C., Kaulback, K., Wood, P.S., Seocharan, I. et al., 2021, 'Symptom cluster is associated with prolonged return-to-play in symptomatic athletes with acute respiratory illness (including COVID-19): A cross-sectional study-AWARE study I', *British Journal of Sports Medicine* 55(20), 1144–1152. <https://doi.org/10.1136/bjsports-2020-103782>
- Sewry, N., Schwellnus, M., Readhead, C., Swanevelde, S. & Jordaan, E., 2022, 'The incidence and transmission of SARS-CoV-2 infection in South African professional rugby players-AWARE II', *Journal of Science and Medicine in Sport* 25(8), 639–643. <https://doi.org/10.1016/j.jsams.2022.06.004>
- Smets, E.M.A., Garssen, B., Bonke, B.D. & De Haes, J.C.J.M., 1995, 'The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue', *Journal of Psychosomatic Research* 39(3), 315–325. [https://doi.org/10.1016/0022-3999\(94\)00125-0](https://doi.org/10.1016/0022-3999(94)00125-0)
- Snyders, C., Schwellnus, M., Sewry, N., Kaulback, K., Wood, P., Seocharan, I. et al., 2023, 'Symptom number and reduced preinfection training predict prolonged return to training after SARS-CoV-2 in athletes: AWARE IV', *Medicine and Science in Sports and Exercise* 55(1), 1–8. <https://doi.org/10.1249/MSS.0000000000003027>
- Steinacker, J.M., Schellenberg, J., Bloch, W., Deibert, P., Friedmann-Bette, B., Grim, C. et al., 2022, 'Recommendations for return-to-sport after COVID-19: Expert consensus', *German Journal of Sports Medicine/Deutsche Zeitschrift für Sportmedizin* 73(4), 127–136. <https://doi.org/10.5960/dzsm.2022.532>
- Van Aerde, N., Van den Berghe, G., Wilmer, A., Gosselink, R. & Hermans, G., 2020, 'Intensive care unit acquired muscle weakness in COVID-19 patients', *Intensive Care Medicine* 46, 2083–2085. <https://doi.org/10.1007/s00134-020-06244-7>
- Vollrath, S., Bizjak, D.A., Zorn, J., Matits, L., Jerg, A., Munk, M. et al., 2022, 'Recovery of performance and persistent symptoms in athletes after COVID-19', *PloS One* 17(12), e0277984. <https://doi.org/10.1371/journal.pone.0277984>



